CJC-1295 research peptide vial

Growth & Performance Research

CJC-1295

Explore CJC-1295 research peptide online, published research information. Explore its mechanism as a GHRH analog, research applications, and safety data.

Catalogue record
OP-891
Intended use
Research use only
Independent COA on this site
Not available

This corporate catalogue does not take orders, display prices or provide dosage instructions.

Research record

Overview

Compound name: CJC-1295

Alternative names: DAC:GHRH (for the long-acting form)

Compound classification: Synthetic peptide; growth hormone–releasing hormone (GHRH) analog

Brief factual description:

CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone designed to stimulate endogenous growth hormone secretion by acting on the pituitary gland. It is studied in both short-acting (no DAC) and long-acting (DAC-modified) forms.

Mechanism of Action

Primary biological targets: Growth hormone–releasing hormone receptors (GHRH-R) on pituitary somatotroph cells

Affected systems: Endocrine (growth hormone and IGF-1 axis)

Receptor selectivity: High specificity for GHRH receptors

Downstream signaling effects:

Stimulation of growth hormone synthesis and pulsatile secretion

Secondary increase in circulating IGF-1 levels

Frequently asked questions

What this record can—and cannot—confirm

Is CJC-1295 approved for human use?

CJC-1295 is supplied strictly for in-vitro laboratory and research use only, not for human consumption or therapeutic use. Regulatory treatment varies by jurisdiction.

How is the purity of CJC-1295 verified?

No independent report for this specific product was available in the public migration source. Request batch-specific documentation from the authorised reseller before relying on a purity claim.

Where can I buy CJC-1295?

Through an OnlinePeptides authorized reseller. Verify any reseller at onlinepeptides.com/verify-reseller/ before purchasing.